Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Modeling the use of SARS-CoV-2 vaccination to safely relax non-pharmaceutical interventions

Alicia N.M. Kraay, View ORCID ProfileMolly E. Gallagher, Yang Ge, Peichun Han, Julia M. Baker, Katia Koelle, View ORCID ProfileAndreas Handel, Benjamin A Lopman
doi: https://doi.org/10.1101/2021.03.12.21253481
Alicia N.M. Kraay
1Emory University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: amullis{at}emory.edu
Molly E. Gallagher
1Emory University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Molly E. Gallagher
Yang Ge
2University of Georgia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peichun Han
1Emory University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julia M. Baker
3Emory University Rollins School of Public Health
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katia Koelle
1Emory University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreas Handel
2University of Georgia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Andreas Handel
Benjamin A Lopman
1Emory University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

In response to the COVID-19 pandemic, widespread non-pharmaceutical interventions (NPIs), including physical distancing, mask wearing, and enhanced hygiene, have been implemented. As of March 2021, three effective vaccines have been approved for emergency use in the United States, with several other vaccines in the pipeline. We use a transmission model to study when and how NPIs could be relaxed in the United States with relative safety as vaccination becomes more widespread. We compare different relaxation scenarios where NPIs begin to relax 0-9 months after vaccination begins for both a one dose and two dose strategy, with historical levels of social interactions being reached within 1 month to 1 year. In our model, vaccination can allow widespread relaxation of NPIs to begin safely within 2 to 9 months, greatly reducing deaths and peak health system burden compared to relaxing NPIs without vaccination. Vaccinated individuals can safely begin to relax NPIs sooner than unvaccinated individuals. The extent of delay needed to safely reopen depends primarily on the rate of vaccine rollout, with the degree of protection against asymptomatic infection playing a secondary role. If a vaccination rate of 3 million doses/day can be achieved, similar to the typical rollout speed of seasonal influenza vaccination, NPIs could begin to be safely relaxed in 2-3 months. With a vaccination rate of 1 million doses/day, a 6–9-month delay is needed. A one dose strategy is preferred if relative efficacy is similar to a two-dose series, but the relative benefit of this strategy is minimal when vaccine rollout is fast. Due to the urgent need to pursue strategies that enable safe relaxation of NPIs, we recommend a two-dose strategy with an initial delay of at least 3 months in relaxing restrictions further, and that the speed of vaccine rollout be given immediate priority.

Competing Interest Statement

B.A.L. reports grants and personal fees from Takeda Pharmaceuticals and personal fees from the World Health Organization outside the submitted work. J.M.B. reports personal fees from the World Health Organization outside the submitted work.

Funding Statement

ANMK, MEG, PH, YG, KK, BAL, and KK were supported by NIH/NIGMS (R01 GM 12480-03S1). ANMK and BAL were supported by NSF (2032084). JMB was supported by Award Number T32AI074492 from NIAID.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

No identifiable data were used and all data included in the paper are publicly available without restriction from web sources. Thus, IRB approval was not needed for this study.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data used in the manuscript are publicly available. Time series data of COVID hospitalizations used to calibrate the model are available from the COVID tracking project at https://covidtracking.com. Serological data are publicly available on CDC’s website at https://covid.cdc.gov/covid-data-tracker/#national-lab. Census data used to initialize the model are also publicly available at: https://www.census.gov/data/tables/2018/demo/age-and-sex/2018-age-sex-composition.html

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted March 13, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Modeling the use of SARS-CoV-2 vaccination to safely relax non-pharmaceutical interventions
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Modeling the use of SARS-CoV-2 vaccination to safely relax non-pharmaceutical interventions
Alicia N.M. Kraay, Molly E. Gallagher, Yang Ge, Peichun Han, Julia M. Baker, Katia Koelle, Andreas Handel, Benjamin A Lopman
medRxiv 2021.03.12.21253481; doi: https://doi.org/10.1101/2021.03.12.21253481
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Modeling the use of SARS-CoV-2 vaccination to safely relax non-pharmaceutical interventions
Alicia N.M. Kraay, Molly E. Gallagher, Yang Ge, Peichun Han, Julia M. Baker, Katia Koelle, Andreas Handel, Benjamin A Lopman
medRxiv 2021.03.12.21253481; doi: https://doi.org/10.1101/2021.03.12.21253481

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (428)
  • Allergy and Immunology (753)
  • Anesthesia (220)
  • Cardiovascular Medicine (3286)
  • Dentistry and Oral Medicine (362)
  • Dermatology (276)
  • Emergency Medicine (478)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1168)
  • Epidemiology (13348)
  • Forensic Medicine (19)
  • Gastroenterology (898)
  • Genetic and Genomic Medicine (5139)
  • Geriatric Medicine (480)
  • Health Economics (781)
  • Health Informatics (3260)
  • Health Policy (1140)
  • Health Systems and Quality Improvement (1189)
  • Hematology (429)
  • HIV/AIDS (1015)
  • Infectious Diseases (except HIV/AIDS) (14618)
  • Intensive Care and Critical Care Medicine (912)
  • Medical Education (476)
  • Medical Ethics (126)
  • Nephrology (522)
  • Neurology (4913)
  • Nursing (262)
  • Nutrition (725)
  • Obstetrics and Gynecology (880)
  • Occupational and Environmental Health (795)
  • Oncology (2517)
  • Ophthalmology (722)
  • Orthopedics (280)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (542)
  • Pediatrics (1299)
  • Pharmacology and Therapeutics (549)
  • Primary Care Research (555)
  • Psychiatry and Clinical Psychology (4198)
  • Public and Global Health (7489)
  • Radiology and Imaging (1703)
  • Rehabilitation Medicine and Physical Therapy (1010)
  • Respiratory Medicine (979)
  • Rheumatology (479)
  • Sexual and Reproductive Health (496)
  • Sports Medicine (424)
  • Surgery (547)
  • Toxicology (72)
  • Transplantation (235)
  • Urology (204)